Post-marketing strategies for medicines [1]

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 1, 2008, Pages 24-25

  Breckenridge, A ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

DRUG APPROVAL; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GOVERNMENT REGULATION; LETTER; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RISK BENEFIT ANALYSIS; RISK MANAGEMENT;

CONSUMER PRODUCT SAFETY; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; DRUG THERAPY; EUROPE; GOVERNMENT REGULATION; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; PROGRAM DEVELOPMENT; RISK ASSESSMENT; UNITED STATES;

EID: 37549041332     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100427     Document Type: Letter

References (1)

1. Avorn, J. Paying for drug approvals. Who's using whom? N. Engl. J. Med. 356, 1697-1700 (2007).